{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:17:55Z","timestamp":1788675475474,"version":"build-2803163510"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,23]]},"DOI":"10.7759\/cureus.79503","type":"journal-article","created":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T16:07:41Z","timestamp":1740326861000},"source":"Crossref","is-referenced-by-count":1,"title":["A Case Report of Encephalopathy With Myoclonus: A Rare Neurologic Side Effect of Ranolazine"],"prefix":"10.7759","author":[{"given":"Shaheer","family":"Arif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"London","family":"Spears","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Shauger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Munim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2019.07.001","article-title":"A clinical approach to diagnosing encephalopathy","volume":"132","author":"Erkkinen MG","year":"2019","unstructured":"Erkkinen MG, Berkowitz AL. A clinical approach to diagnosing encephalopathy. Am J Med. 2019, 132:1142-7. 10.1016\/j.amjmed.2019.07.001","journal-title":"Am J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105408","article-title":"Movement disorders in chronic kidney disease - a descriptive review","volume":"30","author":"Safarpour Y","year":"2021","unstructured":"Safarpour Y, Vaziri ND, Jabbari B. Movement disorders in chronic kidney disease - a descriptive review. J Stroke Cerebrovasc Dis. 2021, 30:105408. 10.1016\/j.jstrokecerebrovasdis.2020.105408","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13238","article-title":"Movement disorders and liver disease","volume":"8","author":"Mulroy E","year":"2021","unstructured":"Mulroy E, Baschieri F, Magrinelli F, Latorre A, Cortelli P, Bhatia KP. Movement disorders and liver disease. Mov Disord Clin Pract. 2021, 8:828-42. 10.1002\/mdc3.13238","journal-title":"Mov Disord Clin Pract"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-022-00698-7","article-title":"The inter-relationship between delirium and dementia: the importance of delirium prevention","volume":"18","author":"Fong TG","year":"2022","unstructured":"Fong TG, Inouye SK. The inter-relationship between delirium and dementia: the importance of delirium prevention. Nat Rev Neurol. 2022, 18:579-96. 10.1038\/s41582-022-00698-7","journal-title":"Nat Rev Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1245632","article-title":"Antiepileptic drug-induced encephalopathy","volume":"78","author":"Hansen N","year":"2010","unstructured":"Hansen N, Finzel M, Block F. Antiepileptic drug-induced encephalopathy. Fortschr Neurol Psychiatr. 2010, 78:590-8. 10.1055\/s-0029-1245632","journal-title":"Fortschr Neurol Psychiatr"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002455","article-title":"Antibiotic-associated encephalopathy","volume":"86","author":"Bhattacharyya S","year":"2016","unstructured":"Bhattacharyya S, Darby RR, Raibagkar P, Gonzalez Castro LN, Berkowitz AL. Antibiotic-associated encephalopathy. Neurology. 2016, 86:963-71. 10.1212\/WNL.0000000000002455","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8357-z","article-title":"The clinical heterogeneity of drug-induced myoclonus: an illustrated review","volume":"264","author":"Janssen S","year":"2017","unstructured":"Janssen S, Bloem BR, van de Warrenburg BP. The clinical heterogeneity of drug-induced myoclonus: an illustrated review. J Neurol. 2017, 264:1559-66. 10.1007\/s00415-016-8357-z","journal-title":"J Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4161\/chan.2.6.7362","article-title":"Block of tetrodotoxin-sensitive, Na(V)1.7 and tetrodotoxin-resistant, Na(V)1.8, Na+ channels by ranolazine","volume":"2","author":"Rajamani S","year":"2008","unstructured":"Rajamani S, Shryock JC, Belardinelli L. Block of tetrodotoxin-sensitive, Na(V)1.7 and tetrodotoxin-resistant, Na(V)1.8, Na+ channels by ranolazine. Channels (Austin). 2008, 2:449-60. 10.4161\/chan.2.6.7362","journal-title":"Channels (Austin)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI40801","article-title":"Human voltage-gated sodium channel mutations that cause inherited neuronal and muscle channelopathies increase resurgent sodium currents","volume":"120","author":"Jarecki BW","year":"2010","unstructured":"Jarecki BW, Piekarz AD, Jackson JO 2nd, Cummins TR. Human voltage-gated sodium channel mutations that cause inherited neuronal and muscle channelopathies increase resurgent sodium currents. J Clin Invest. 2010, 120:369-78. 10.1172\/JCI40801","journal-title":"J Clin Invest"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645050-00003","article-title":"Clinical pharmacokinetics of ranolazine","volume":"45","author":"Jerling M","year":"2006","unstructured":"Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet. 2006, 45:469-91. 10.2165\/00003088-200645050-00003","journal-title":"Clin Pharmacokinet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1152","article-title":"Neurologic adverse effects of ranolazine in an elderly patient with renal impairment","volume":"33","author":"Southard RA","year":"2013","unstructured":"Southard RA, M Blum R, Bui AH, Blankstein R. Neurologic adverse effects of ranolazine in an elderly patient with renal impairment. Pharmacotherapy. 2013, 33:e9-13. 10.1002\/phar.1152","journal-title":"Pharmacotherapy"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.14740\/jmc2774w","article-title":"Ranolazine and hallucinations","volume":"8","author":"Kalra S","year":"2017","unstructured":"Kalra S, Arora Z, Nielsen C. Ranolazine and hallucinations. J Med Cas. 2017, 8:90-2. 10.14740\/jmc2774w","journal-title":"J Med Cas"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/451206","article-title":"A rare neurological complication of ranolazine","volume":"2013","author":"Porhomayon J","year":"2013","unstructured":"Porhomayon J, Zadeii G, Yarahmadi A. A rare neurological complication of ranolazine. Case Rep Neurol Med. 2013, 2013:451206. 10.1155\/2013\/451206","journal-title":"Case Rep Neurol Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/345395-a-case-report-of-encephalopathy-with-myoclonus-a-rare-neurologic-side-effect-of-ranolazine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T16:07:43Z","timestamp":1740326863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/345395-a-case-report-of-encephalopathy-with-myoclonus-a-rare-neurologic-side-effect-of-ranolazine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,23]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.79503","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,23]]}}}